Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
21
HKPD Quote, Financials, Valuation and Earnings
Last price:
$0.77
Seasonality move
:
--
Day range:
$0.75 - $0.83
52-week range:
$0.68 - $3.79
Dividend yield:
0%
P/E ratio:
8.18x
P/S ratio:
0.75x
P/B ratio:
2.30x
Volume:
24.1K
Avg. volume:
117.9K
1-year change:
--
Market cap:
$8.5M
Revenue:
$16.7M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.38 |
|
PRE
Prenetics Global Ltd.
|
$45.9M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HKPD
Cellyan Biotechnology Ltd.
|
$0.78 | -- | $8.5M | 8.18x | $0.00 | 0% | 0.75x |
|
HCM
HUTCHMED (China) Ltd.
|
$14.72 | $22.38 | $2.5B | 4.92x | $0.00 | 0% | 4.25x |
|
PRE
Prenetics Global Ltd.
|
$15.53 | $26.00 | $261.3M | -- | $0.00 | 0% | 3.02x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$45.79 | -- | $22.6B | -- | $0.00 | 0% | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
$18.22 | -- | $16.3B | 31.84x | $0.13 | 1.26% | 3.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | 0.000 | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.158 | -- | 4.41x |
|
PRE
Prenetics Global Ltd.
|
1.29% | 5.284 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 18.151 | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
23.1% | -0.664 | -- | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
Cellyan Biotechnology Ltd. vs. Competitors
-
Which has Higher Returns HKPD or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Cellyan Biotechnology Ltd.'s net margin of --. Cellyan Biotechnology Ltd.'s return on equity of -- beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital HKPDCellyan Biotechnology Ltd.-- -- -- HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About HKPD or HCM?
Cellyan Biotechnology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.38 which suggests that it could grow by 52.07%. Given that HUTCHMED (China) Ltd. has higher upside potential than Cellyan Biotechnology Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Cellyan Biotechnology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDCellyan Biotechnology Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is HKPD or HCM More Risky?
Cellyan Biotechnology Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.418, suggesting its less volatile than the S&P 500 by 58.206%.
-
Which is a Better Dividend Stock HKPD or HCM?
Cellyan Biotechnology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellyan Biotechnology Ltd. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or HCM?
Cellyan Biotechnology Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Cellyan Biotechnology Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Cellyan Biotechnology Ltd.'s price-to-earnings ratio is 8.18x while HUTCHMED (China) Ltd.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellyan Biotechnology Ltd. is 0.75x versus 4.25x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- -- HCMHUTCHMED (China) Ltd.4.25x 4.92x -- --
-
Which has Higher Returns HKPD or PRE?
Prenetics Global Ltd. has a net margin of -- compared to Cellyan Biotechnology Ltd.'s net margin of -28.82%. Cellyan Biotechnology Ltd.'s return on equity of -- beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital HKPDCellyan Biotechnology Ltd.-- -- -- PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About HKPD or PRE?
Cellyan Biotechnology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 99.61%. Given that Prenetics Global Ltd. has higher upside potential than Cellyan Biotechnology Ltd., analysts believe Prenetics Global Ltd. is more attractive than Cellyan Biotechnology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDCellyan Biotechnology Ltd.0 0 0 PREPrenetics Global Ltd.1 0 0 -
Is HKPD or PRE More Risky?
Cellyan Biotechnology Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HKPD or PRE?
Cellyan Biotechnology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellyan Biotechnology Ltd. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or PRE?
Cellyan Biotechnology Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Cellyan Biotechnology Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Cellyan Biotechnology Ltd.'s price-to-earnings ratio is 8.18x while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellyan Biotechnology Ltd. is 0.75x versus 3.02x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- -- PREPrenetics Global Ltd.3.02x -- $23.6M -$6.8M
-
Which has Higher Returns HKPD or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to Cellyan Biotechnology Ltd.'s net margin of --. Cellyan Biotechnology Ltd.'s return on equity of -- beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HKPDCellyan Biotechnology Ltd.-- -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About HKPD or RGC?
Cellyan Biotechnology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cellyan Biotechnology Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Cellyan Biotechnology Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDCellyan Biotechnology Ltd.0 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is HKPD or RGC More Risky?
Cellyan Biotechnology Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HKPD or RGC?
Cellyan Biotechnology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellyan Biotechnology Ltd. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or RGC?
Cellyan Biotechnology Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Cellyan Biotechnology Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Cellyan Biotechnology Ltd.'s price-to-earnings ratio is 8.18x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellyan Biotechnology Ltd. is 0.75x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
-
Which has Higher Returns HKPD or SBHMY?
Sino Biopharmaceutical Ltd. has a net margin of -- compared to Cellyan Biotechnology Ltd.'s net margin of --. Cellyan Biotechnology Ltd.'s return on equity of -- beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital HKPDCellyan Biotechnology Ltd.-- -- -- SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About HKPD or SBHMY?
Cellyan Biotechnology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cellyan Biotechnology Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Cellyan Biotechnology Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HKPDCellyan Biotechnology Ltd.0 0 0 SBHMYSino Biopharmaceutical Ltd.0 0 0 -
Is HKPD or SBHMY More Risky?
Cellyan Biotechnology Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.590, suggesting its less volatile than the S&P 500 by 40.969%.
-
Which is a Better Dividend Stock HKPD or SBHMY?
Cellyan Biotechnology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.26% to investors and pays a quarterly dividend of $0.13 per share. Cellyan Biotechnology Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 55.99% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HKPD or SBHMY?
Cellyan Biotechnology Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. Cellyan Biotechnology Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, Cellyan Biotechnology Ltd.'s price-to-earnings ratio is 8.18x while Sino Biopharmaceutical Ltd.'s PE ratio is 31.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellyan Biotechnology Ltd. is 0.75x versus 3.87x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- -- SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
